

**IPAR**



**Publicly Available Assessment Report for a  
Veterinary Medicinal Product**

---

Doramax 10 mg/ml Solution for Injection for Cattle, Sheep and Pigs

## PRODUCT SUMMARY

EU Procedure number	IE/V/0770/001/DC
Name, strength and pharmaceutical form	Doramax 10 mg/ml Solution for Injection for Cattle, Sheep and Pigs
Active substance(s)	Doramectin
Applicant	Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway, Ireland
Legal basis of application	Article 13 (1) of Directive 2001/82/EC
Date of completion of procedure	29/06/2022
Target species	Cattle, Sheep and Pigs
Indication for use	<p><b>CATTLE:</b> For treatment of gastrointestinal roundworms, lungworms, eyeworms, warbles, lice, mange mites and ticks.</p> <p><u>Gastrointestinal roundworms (adults and fourth stage larvae unless otherwise indicated):</u>  <i>Ostertagia ostertagi</i> (including inhibited larvae)  <i>O. lyrata</i> (adults only)  <i>Haemonchus placei</i>  <i>Trichostrongylus axei</i>  <i>T. colubriformis</i>  <i>Cooperia oncophora</i>  <i>C. pectinata</i> (adults only)  <i>C. punctata</i>  <i>C. surnabada</i> (syn. <i>mcmasteri</i>)  <i>N. spathiger</i> (adults only)  <i>Bunostomum phlebotomum</i> (adults only)  <i>Strongyloides papillosus</i> (adults only)  <i>Oesophagostomum radiatum</i>  <i>Trichuris</i> spp. (adults only)</p> <p><u>Lungworms: (adults and fourth stage larvae)</u>  <i>Dictyocaulus viviparus</i></p> <p><u>Eyeworms: (adults only)</u>  <i>Thelazia</i> spp.</p> <p><u>Warbles: (parasitic stages)</u>  <i>Hypoderma bovis</i>  <i>H. lineatum</i></p> <p><u>Sucking lice:</u>  <i>Haematopinus eurytenuis</i>  <i>Linognathus vituli</i>  <i>Solenopotes capillatus</i></p> <p><u>Mange mites:</u>  <i>Psoroptes bovis</i>  <i>Sarcoptes scabiei</i></p> <p>The product may also be used as an aid in the treatment of <i>Nematodirus helvetianus</i>, biting lice (<i>Damalinea bovis</i>), the tick <i>Ixodes ricinus</i> and the mange mite <i>Chorioptes bovis</i>.</p>

Following product administration, efficacy against re-infection with the following parasites persists for the period indicated:

Species	Days
<i>Bunostomum phlebotomum</i>	22
<i>Cooperia oncophora</i>	21
<i>Dictyocaulus viviparus</i>	35
<i>Haemonchus placei</i> (adults only)	28
<i>Linognathus vituli</i>	28
<i>Oesophagostomum radiatum</i>	21
<i>Ostertagia ostertagi</i>	35
<i>Psoroptes bovis</i>	42
<i>Trichostrongylus axei</i>	28

**SHEEP:**

For treatment of gastrointestinal roundworms, lungworms, nasal bots and mange mites

Gastrointestinal roundworms (adults and fourth stage larvae (L4) unless otherwise indicated):

*Bunostomum trigonocephalum* (adults only)

*Chabertia ovina*

*Cooperia curticei* (L4 only)

*C. oncophora*

*Gaigeria pachyscelis*

*Haemonchus contortus*

*Nematodirus battus* (L4 only)

*N. filicollis* (adults only)

*N. spathiger*

*Ostertagia (Teladorsagia) circumcincta*\*

*Ostertagia (Teladorsagia) trifurcata* (adults only)

*Oesophagostomum venulosum* (adults only)

*O. columbianum*

*Strongyloides papillosus*

*Trichostrongylus axei*

*T. colubriformis*

*T. vitrinus*

*Trichuris* spp. (adults only)

\*Inhibited larval stages (L4), including strains that are benzimidazole resistant, are also treated.

Lungworms (adults and fourth stage larvae (L4))

*Cystocaulus ocreatus* (adults only)

*Dictyocaulus filaria*

*Muellerius capillaris* (adults only)

*Neostrongylus linearis* (adults only)

*Protostrongylus rufescens* (adults only)

Nasal bots (1st, 2nd and 3rd instar larvae)

*Oestrus ovis*

Mange mites

*Psoroptes ovis*

**PIGS:**

For treatment of gastrointestinal roundworms, lungworms, kidney worms, sucking lice and mange mites in pigs.

	<u>Gastrointestinal roundworms (adults and fourth stage larvae)</u> <i>Hyostromylus rubidus</i> <i>Ascaris suum</i> <i>Strongyloides ransomi</i> (adults only) <i>Oesophagostomum dentatum</i> <i>Oesophagostomum quadrispinulatum</i>  <u>Lungworms</u> <i>Metastrongylus</i> spp. (adults only)  <u>Kidney worms</u> <i>Stephanurus dentatus</i> (adults only)  <u>Sucking Lice</u> <i>Haematopinus suis</i>  <u>Mange Mites</u> <i>Sarcoptes scabiei</i>  The product protects pigs against infection or reinfection with <i>Sarcoptes scabiei</i> for 18 days.
ATC vet code	QP 54AA03
Concerned Member States	BE, DK, DE, FR, HU, IT, NL, PL, PT, ES

## PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

### I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall benefit/risk analysis is in favour of granting a marketing authorisation.

### II. QUALITY ASPECTS

#### A. Qualitative and Quantitative Particulars

The product contains 10 mg/ml doramectin and the excipients ethyl oleate, sesame oil, refined and butylhydroxyanisole (E320). The container/closure system is 50 ml, 250 ml and 500 ml Type II amber glass multi-dose vials, with chlorobutyl rubber stoppers secured with an aluminium cap.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

#### B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.

### **C. Control of Starting Materials**

The active substance is doramectin, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification has been provided.

#### *Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies*

Compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

### **D. Control on Intermediate Products**

Not applicable.

### **E. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods has been provided.

Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

### **F. Stability**

Stability data on the active substance has been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product has been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

### **G. Other Information**

Not applicable

## **III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

### **III.A Safety Testing**

This generic application was submitted in accordance with paragraph 1 of Article 13 of Directive 2001/82/EC, as amended. The reference product cited by the applicant is Zearl 10 mg/ml Solution for Injection for Cattle and Sheep (VPA10047/027/001), with reference also made to the additional, related product Zearl 10 mg/ml Solution for Injection for Pigs (VPA10047/028/001). Both products have been authorised within the Community for not less than ten years and can therefore be accepted as valid reference product(s) in this generic application.

#### **Pharmacological Studies**

An exemption from the need to conduct *in vivo* bioequivalence studies in the target species was accepted in accordance with section 7.1 of the CVMP Guideline on the conduct of bioequivalence studies.

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, results of pharmacological studies are not required.

#### **Toxicological Studies**

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, results of toxicological studies are not required.

#### **User Safety**

The applicant has provided a user safety assessment in compliance with the relevant guideline. The potential risks will be identical to those of the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

- Do not smoke or eat while handling the product.
- Wash hands after use.
- Take care to avoid accidental self-administration – seek medical attention should any specific signs be noticed.

- Advice to medical practitioners: In case of accidental self injection specific symptoms have rarely been observed and therefore any cases should be treated symptomatically.

## Environmental Risk Assessment

### Phase I

The calculated predicted environmental concentrations in soil (PEC<sub>soil</sub>) for all target species were <100 µg/kg. However, a Phase II ERA is required as the product is an ectoparasiticide and endoparasiticide and the target species, cattle and sheep, are reared on pasture.

### Phase II

A Phase II Tier A and B assessment was conducted the results of which are summarised below.

<b>Physico-chemical properties</b>	
<b>Study type</b>	<b>Result</b>
Vapour pressure	9.2 x 10 <sup>-6</sup> Pa (20°C)
Water solubility	2.075 mg/l (pH 5.69, 20 ± 0.5 °C)
Dissociation constants in water pKa	None could be determined at pH 1-12 at 20°C
n-Octanol/Water Partition Coefficient logP <sub>ow</sub>	logK <sub>ow</sub> = 6.71

<b>Environmental fate</b>	
Soil Adsorption/Desorption	K <sub>oc</sub> = 4615 ml/g K <sub>d</sub> = 53.6 ml/g
Aerobic and Anaerobic Transformation in Soil	DT <sub>50</sub> = 30.7 days (20 ± 2°C)

<b>Effect studies</b>			
<b>Study type</b>	<b>Endpoint</b>	<b>Result</b>	<b>Unit</b>
Algae growth inhibition test/ <i>Pseudokirchneriella subcapitata</i>	EC <sub>50</sub>	472	µg/l
<i>Daphnia</i> spp. immobilisation	EC <sub>50</sub>	0.0107	µg/l
Fish, acute toxicity/ <i>Oncorhynchus mykiss</i>	LC <sub>50</sub>	14.1	µg/l
Soil microorganisms: Nitrogen transformation test (28 days)	% effect	<25%	
Earthworm/ <i>Eisenia foetida</i> reproduction	NOEC	500	µg/kg dry weight
Sediment dwelling organism/ <i>Chironomus riparius</i>	NOEC	9.03	µg/kg dry weight
Dung fly larvae/ <i>Musca autumnalis</i>	EC <sub>50</sub>	5.5	µg/kg wet weight
Dung beetle larvae/ <i>Onthophagus taurus</i>	EC <sub>50</sub>	518	µg/kg wet weight
Bioaccumulation in fish/ <i>Oncorhynchus mykiss</i>	BCF	347	L/kg

### Risk characterisation

The Predicted Environmental Concentration (PEC) for each compartment was calculated in accordance with guideline requirements.

Using the relevant assessment factors, predicted no effect concentrations (PNECs) were calculated and compared with the PEC values to determine a risk quotient (RQ) for each compartment.

The risk characterisation resulted in risk quotients below 1 for the groundwater and soil compartments indicating that the product will not pose a risk to those compartments when used as recommended.

The results of the assessment for the surface water and dung compartments indicate that a risk for the environment potentially exists for:

- dung dwelling organisms exposed to dung produced by treated pasture animals,
- aquatic invertebrates in surface waters in the case of run-off and drainage and direct excretion,

- sediment dwelling organisms in the case of direct excretion.

Consequently, the following risk mitigation measures are required for this product:

Doramectin is very toxic to dung fauna and aquatic organisms and may accumulate in sediments.

The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of doramectin (and products of the same anthelmintic class) in cattle and sheep.

The risk to aquatic ecosystems will be further reduced by keeping treated cattle away from water bodies for two to five weeks after treatment.

#### **PBT Assessment**

An assessment of the compound in terms of potential for Persistence, Bioaccumulation and Toxicity (PBT) for the environment or whether it may be considered as being very Persistent and very Bioaccumulative (vPvB) was performed.

The log  $K_{ow}$  of doramectin was demonstrated to be 6.71.

The compound is not considered to be either PBT or vPvB.

#### **Conclusion**

Based on the data provided in the ERA, a risk to the aquatic and terrestrial environment cannot be excluded. Therefore suitable risk mitigation measures and/or advice were included in the SPC for this product.

### **III.B Residues Documentation**

#### **Residue Studies**

No residue depletion studies were provided.

#### **MRLs**

Doramectin is listed in Table I of the Annex to Commission Regulation (EU) No 37/2010 as follows:

<b>Pharmacologically active substance</b>	<b>Marker residue</b>	<b>Animal species</b>	<b>MRL</b>	<b>Target tissues</b>	<b>Other provisions</b>
Doramectin	Doramectin	All mammalian food producing species	40 µg/kg 150 µg/kg 100 µg/kg 60 µg/kg	Muscle Fat Liver Kidney	No entry

#### **Withdrawal Periods**

This generic application was submitted according to Article 13(1) of Directive 2001/82/EC as amended. The withdrawal periods are the same as those for the reference product, as follows:

##### **CATTLE:**

Meat and offal: 70 days

Not permitted for use in lactating animals producing milk for human consumption.

Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.

##### **SHEEP:**

Meat and offal: 70 days

Not permitted for use in lactating animals producing milk for human consumption.

Do not use in pregnant ewes, which are intended to produce milk for human consumption, within 70 days of expected parturition.

##### **PIGS:**

Meat and offal: 77 days

### **IV. CLINICAL ASSESSMENT**

#### **IV.A Pre-Clinical Studies**

An exemption from the need to conduct *in vivo* bioequivalence studies in the target species was accepted in accordance with section 7.1 of the CVMP Guideline on the conduct of bioequivalence studies.

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, results of pre-clinical studies are not required.

***Tolerance in the Target Species of Animals***

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, tolerance studies are not required.

The product literature accurately reflects the type and incidence of adverse effects which might be expected (none).

***Resistance***

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, the resistance profile of the product will be the same as that of the reference product.

Adequate, updated warnings and precautions appear on the product literature.

***IV.B Clinical Studies***

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been accepted, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

**V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

**VI. POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

**Changes:**

None.